FDA designated eli lilly and co drug as an orphan drug for STXBP1 brain disease. On October 19, the FDA granted the drug the designation, with the generic name of "recombinant adeno-associated virus capsid enclosing the human Stxbp1 transgene single-stranded DNA construct". If the FDA approves the orphan drug for the treatment of rare diseases, the drug will enjoy 7 years of market exclusivity.
礼来治疗药物被 FDA 授予孤儿药地位
Eli Lilly and Co's treatment drug has been granted orphan drug status by the FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated